The use of dupilumab in difficult-to-treat areas of atopic dermatitis: lessons from real-world studies

杜皮鲁玛 特应性皮炎 医学 湿疹面积及严重程度指数 生活质量(医疗保健) 不利影响 皮肤病科 临床试验 疾病 重症监护医学 免疫失调 梅德林 微生物群 免疫学 敏化 性器官 过敏 贾纳斯激酶 临床意义 马拉色菌 转化研究 皮肤科生活质量指数 脱敏(药物) 叙述性评论
作者
Michela D’Agostino,Luca Potestio,Cataldo Patruno,Emanuela Martina,Maddalena Napolitano
出处
期刊:Clinical and Experimental Dermatology [Oxford University Press]
卷期号:51 (2): 202-211
标识
DOI:10.1093/ced/llaf441
摘要

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease with a big impact on quality of life. Despite major therapeutic advances, the involvement of difficult-to-treat areas such as the head and neck, hands and feet, and genital region remains a significant clinical challenge. Dupilumab, the first biologic approved for moderate-to-severe AD, has shown remarkable efficacy in clinical trials and real-world settings, but variable outcomes have been reported on sensitive areas of the body. This narrative review synthesizes evidence from real-world studies evaluating dupilumab in patients with AD affecting difficult-to-treat areas. Data indicate that dupilumab improves signs and symptoms for the majority of patients, with substantial benefits for quality of life and disease control. However, a subset of patients may experience suboptimal responses or paradoxical reactions, such as dupilumab-associated head and neck dermatitis (DAHND), often linked to Malassezia sensitization or alternative immune pathways. Similarly, although many studies confirm dupilumab effectiveness in chronic hand and foot eczema, treatments that have failed occur, sometimes requiring transition to Janus kinase inhibitors. Involvement of the genital area, a frequently underrecognized manifestation, generally responds well to dupilumab, although alternative biologics or small molecules may be needed in patients with resistant cases. Overall, real-world data highlight both the strengths and limitations of dupilumab in challenging anatomical sites, stressing the need for individualized therapeutic decisions. Awareness of variable responses, adverse event profiles and emerging alternatives is crucial for optimizing outcomes in patients with moderate-to-severe AD.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
科研通AI6.3应助会飞的猪qq采纳,获得10
2秒前
2秒前
眯眯眼的士萧完成签到,获得积分10
2秒前
洁净梦安完成签到 ,获得积分10
4秒前
QLG发布了新的文献求助10
4秒前
5秒前
5秒前
科研通AI6.2应助dong采纳,获得10
5秒前
帅123完成签到 ,获得积分10
7秒前
科研通AI6.2应助凌雪采纳,获得10
7秒前
8秒前
斯文败类应助奶冻采纳,获得10
9秒前
酷波er应助caas6采纳,获得10
9秒前
小马甲应助科研通管家采纳,获得10
10秒前
aaaa应助科研通管家采纳,获得10
10秒前
sumugeng完成签到,获得积分10
10秒前
aaaa应助科研通管家采纳,获得10
10秒前
隐形曼青应助科研通管家采纳,获得10
10秒前
脑洞疼应助科研通管家采纳,获得10
10秒前
HHHHTTTT应助科研通管家采纳,获得10
10秒前
wp4605应助科研通管家采纳,获得20
10秒前
烟花应助科研通管家采纳,获得10
10秒前
小二郎应助科研通管家采纳,获得10
10秒前
王人捷应助科研通管家采纳,获得10
10秒前
牛大佳发布了新的文献求助10
10秒前
浮云应助科研通管家采纳,获得10
10秒前
Kao应助ale采纳,获得10
11秒前
qiongqiong发布了新的文献求助10
11秒前
完美世界应助科研通管家采纳,获得10
11秒前
烁然应助科研通管家采纳,获得10
11秒前
Lucas应助科研通管家采纳,获得50
11秒前
Owen应助科研通管家采纳,获得10
11秒前
JamesPei应助科研通管家采纳,获得10
11秒前
田様应助科研通管家采纳,获得10
11秒前
科研通AI2S应助科研通管家采纳,获得10
11秒前
wangjie完成签到,获得积分10
11秒前
Hello应助科研通管家采纳,获得10
11秒前
orixero应助科研通管家采纳,获得10
11秒前
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Organic Chemistry, 5th Edition 1000
Nondestructive Testing Handbook: Vol. 4, Thermal and Infrared Testing (IR), 4th ed 800
作者名:Kristopher P. Plain,悉尼大学的,目前只能查到其四篇论文,想找到其博士论文 590
Évora na Idade Média 555
Soil mites of the family Rhagidiidae (Actinedida: Eupodoidea). Morphology, Systematics, Ecology 520
Matrix Methods in Data Mining and Pattern Recognition Second Edition 510
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7371360
求助须知:如何正确求助?哪些是违规求助? 8978940
关于积分的说明 19089199
捐赠科研通 7013353
什么是DOI,文献DOI怎么找? 3225063
关于科研通互助平台的介绍 2388685
邀请新用户注册赠送积分活动 2205751